FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313551710> ?p ?o ?g. }

• W4313551710 abstract "Abstract Introduction Infant HIV prophylaxis with broadly neutralizing anti‐HIV antibodies (bNAbs) could provide long‐acting protection against vertical transmission. We sought to estimate the potential clinical impact and cost‐effectiveness of hypothetical bNAb prophylaxis programmes for children known to be HIV exposed at birth in three sub‐Saharan African settings. Methods We conducted a cost‐effectiveness analysis using the CEPAC‐Pediatric model, simulating cohorts of infants from birth through death in Côte d'Ivoire, South Africa and Zimbabwe. These settings were selected to reflect a broad range of HIV care cascade characteristics, antenatal HIV prevalence and budgetary constraints. We modelled strategies targeting bNAbs to only WHO‐designated “high‐risk” HIV‐exposed infants ( HR‐HIVE ) or to all HIV‐exposed infants ( HIVE ). We compared four prophylaxis approaches within each target population: standard of care oral antiretroviral prophylaxis ( SOC ), and SOC plus bNAbs at birth ( 1‐dose ), at birth and 3 months ( 2‐doses ), or every 3 months throughout breastfeeding ( Extended ). Base‐case model inputs included bNAb efficacy (60%/dose), effect duration (3 months/dose) and costs ($60/dose), based on published literature. Outcomes included paediatric HIV incidence and incremental cost‐effectiveness ratios (ICERs) calculated from discounted life expectancy and lifetime HIV‐related costs. Results The model projects that bNAbs would reduce absolute infant HIV incidence by 0.3–2.2% (9.6–34.9% relative reduction), varying by country, prophylaxis approach and target population. In all three settings, HR‐HIVE–1‐dose would be cost‐saving compared to SOC . Using a 50% GDP per capita ICER threshold, HIVE‐Extended would be cost‐effective in all three settings with ICERs of $497/YLS in Côte d'Ivoire, $464/YLS in South Africa and $455/YLS in Zimbabwe. In all three settings, bNAb strategies would remain cost‐effective at costs up to $200/dose if efficacy is ≥30%. If the bNAb effect duration were reduced to 1 month, the cost‐effective strategy would become HR‐HIVE–1‐dose in Côte d'Ivoire and Zimbabwe and HR‐HIVE–2‐doses in South Africa. Findings regarding the cost‐effectiveness of bNAb implementation strategies remained robust in sensitivity analyses regarding breastfeeding duration, maternal engagement in postpartum care, early infant diagnosis uptake and antiretroviral treatment costs. Conclusions At current efficacy and cost estimates, bNAb prophylaxis for HIV‐exposed children in sub‐Saharan African settings would be a cost‐effective intervention to reduce vertical HIV transmission." @default.
• W4313551710 created "2023-01-06" @default.
• W4313551710 creator A5010772046 @default.
• W4313551710 creator A5014423895 @default.
• W4313551710 creator A5015956535 @default.
• W4313551710 creator A5039731482 @default.
• W4313551710 creator A5043843002 @default.
• W4313551710 creator A5049003583 @default.
• W4313551710 creator A5054883892 @default.
• W4313551710 creator A5056778092 @default.
• W4313551710 creator A5065596403 @default.
• W4313551710 creator A5074313423 @default.
• W4313551710 creator A5082620613 @default.
• W4313551710 creator A5084732324 @default.
• W4313551710 creator A5085388820 @default.
• W4313551710 date "2023-01-01" @default.
• W4313551710 modified "2023-10-15" @default.
• W4313551710 title "Cost‐effectiveness of broadly neutralizing antibody prophylaxis for HIV‐exposed infants in sub‐Saharan African settings" @default.
• W4313551710 cites W1983742602 @default.
• W4313551710 cites W2038183880 @default.
• W4313551710 cites W2038477306 @default.
• W4313551710 cites W2047775864 @default.
• W4313551710 cites W2049475968 @default.
• W4313551710 cites W2108823596 @default.
• W4313551710 cites W2110450357 @default.
• W4313551710 cites W2126184004 @default.
• W4313551710 cites W2128911553 @default.
• W4313551710 cites W2135662203 @default.
• W4313551710 cites W2144396940 @default.
• W4313551710 cites W2157450041 @default.
• W4313551710 cites W2160469547 @default.
• W4313551710 cites W2302590903 @default.
• W4313551710 cites W2308542537 @default.
• W4313551710 cites W2316093128 @default.
• W4313551710 cites W2555080176 @default.
• W4313551710 cites W2610581664 @default.
• W4313551710 cites W2611116815 @default.
• W4313551710 cites W2612582782 @default.
• W4313551710 cites W2617945291 @default.
• W4313551710 cites W2755179393 @default.
• W4313551710 cites W2774008425 @default.
• W4313551710 cites W2777435694 @default.
• W4313551710 cites W2795330130 @default.
• W4313551710 cites W2803382975 @default.
• W4313551710 cites W2803655842 @default.
• W4313551710 cites W2890435716 @default.
• W4313551710 cites W2900113073 @default.
• W4313551710 cites W2901236561 @default.
• W4313551710 cites W2912457615 @default.
• W4313551710 cites W2913779566 @default.
• W4313551710 cites W2921500025 @default.
• W4313551710 cites W2922751638 @default.
• W4313551710 cites W2946581110 @default.
• W4313551710 cites W2972779065 @default.
• W4313551710 cites W2984342233 @default.
• W4313551710 cites W2999692731 @default.
• W4313551710 cites W3003990975 @default.
• W4313551710 cites W3037446416 @default.
• W4313551710 cites W3087152757 @default.
• W4313551710 cites W3093551692 @default.
• W4313551710 cites W3113130098 @default.
• W4313551710 cites W3125384992 @default.
• W4313551710 cites W3138945586 @default.
• W4313551710 cites W3147009805 @default.
• W4313551710 cites W3157202113 @default.
• W4313551710 cites W3176793822 @default.
• W4313551710 cites W3199323201 @default.
• W4313551710 cites W3217021952 @default.
• W4313551710 cites W4282598306 @default.
• W4313551710 doi "https://doi.org/10.1002/jia2.26052" @default.
• W4313551710 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36604316" @default.
• W4313551710 hasPublicationYear "2023" @default.
• W4313551710 type Work @default.
• W4313551710 citedByCount "1" @default.
• W4313551710 countsByYear W43135517102023 @default.
• W4313551710 crossrefType "journal-article" @default.
• W4313551710 hasAuthorship W4313551710A5010772046 @default.
• W4313551710 hasAuthorship W4313551710A5014423895 @default.
• W4313551710 hasAuthorship W4313551710A5015956535 @default.
• W4313551710 hasAuthorship W4313551710A5039731482 @default.
• W4313551710 hasAuthorship W4313551710A5043843002 @default.
• W4313551710 hasAuthorship W4313551710A5049003583 @default.
• W4313551710 hasAuthorship W4313551710A5054883892 @default.
• W4313551710 hasAuthorship W4313551710A5056778092 @default.
• W4313551710 hasAuthorship W4313551710A5065596403 @default.
• W4313551710 hasAuthorship W4313551710A5074313423 @default.
• W4313551710 hasAuthorship W4313551710A5082620613 @default.
• W4313551710 hasAuthorship W4313551710A5084732324 @default.
• W4313551710 hasAuthorship W4313551710A5085388820 @default.
• W4313551710 hasBestOaLocation W43135517101 @default.
• W4313551710 hasConcept C112299071 @default.
• W4313551710 hasConcept C112930515 @default.
• W4313551710 hasConcept C120665830 @default.
• W4313551710 hasConcept C121332964 @default.
• W4313551710 hasConcept C127598652 @default.
• W4313551710 hasConcept C133925201 @default.
• W4313551710 hasConcept C187212893 @default.
• W4313551710 hasConcept C203014093 @default.
• W4313551710 hasConcept C2776283161 @default.
• W4313551710 hasConcept C2908647359 @default.

• next